CCX140-B is a specific CCR2 inhibitor, and as illustrated in Fig. 3b, c, there were no significant difference in the tumor volumes between the BTZ and CCX + BTZ groups, which indicated that blocking the CCL2–CCR2 axis in MM cells scarcely influenced the effect of bortezomib. This evidence concerns the gene CCL2 and neoplasm.